Browsing Tag
Dr. Reddy’s Laboratories Ltd
8 posts
Is Dr. Reddy’s oncology pipeline strong enough to compete with global innovators in 2025 and beyond?
Explore Dr. Reddy’s oncology pipeline, biosimilars approvals, and revenue outlook—can the Hyderabad-based pharma firm compete with global cancer drug innovators?
Can Dr. Reddy’s GLP-1 strategy position it as a key player in the global metabolic drug race?
Explore Dr. Reddy’s GLP‑1 pipeline, patent strategy, and emerging market focus—can the Hyderabad-based pharma firm lead India’s metabolic drug push?
Can Dr. Reddy’s PSAI business quietly power its next phase of global pharmaceutical growth?
Can Dr. Reddy’s PSAI division unlock global API and CDMO growth? Explore revenues, strategy, investor sentiment, and vertical integration outlook in 2025.
How the nicotine replacement therapy acquisition reshaped Dr. Reddy’s Europe growth strategy
See how Dr. Reddy’s ₹5,000 crore NRT acquisition is transforming its Europe strategy—brand-led growth, consumer health margins, and global OTC ambitions.
Can Dr. Reddy’s build a biosimilars portfolio that rivals Biocon and global MNCs in regulated markets?
Explore Dr. Reddy’s biosimilars pipeline, regulatory milestones, and commercial strategy—can it compete with Biocon and global pharma giants in 2025?
Dr. Reddy’s company profile: Respiratory, generics, and global drug pipeline in 2025
Explore Dr. Reddy’s FY25 financials, drug pipeline, and global expansion strategy—see why it’s gaining attention in pharma investment circles.
Dr. Reddy’s Laboratories, Bayer to distribute Vericiguat for heart failure in India
In a significant move within the Indian healthcare sector, Dr. Reddy’s Laboratories Ltd. and Bayer have announced a…
Dr. Reddy’s Laboratories partners with Sanofi Healthcare India for vaccine distribution
In a landmark move aimed at enhancing healthcare access across India, Dr. Reddy’s Laboratories Ltd. has announced an…